BioAtla (NASDAQ:BCAB – Get Free Report) is expected to be releasing its Q3 2026 results on Thursday, November 12th. Analysts expect BioAtla to announce earnings of ($7.00) per share and revenue of $5.59 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.
BioAtla (NASDAQ:BCAB – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.50) by $8.64. The business had revenue of $6.50 million during the quarter, compared to analyst estimates of $6.50 million.
BioAtla Trading Down 12.4%
Shares of BCAB stock opened at $1.83 on Wednesday. The company’s fifty day simple moving average is $1.58 and its 200-day simple moving average is $4.70. BioAtla has a 52 week low of $1.07 and a 52 week high of $71.50. The company has a market cap of $3.05 million, a PE ratio of -0.07 and a beta of 0.53.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioAtla in a research report on Monday, August 31st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $200.00.
View Our Latest Analysis on BCAB
BioAtla Company Profile
BioAtla, Inc. was a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company used its Conditionally Active Biologics (CAB) platform to design antibody-based medicines intended to become active primarily within the tumor microenvironment, with the goal of improving treatment effectiveness while limiting effects on healthy tissue. BioAtla’s investigational pipeline included antibody-drug conjugates and immune-modulating therapies. Its lead programs included mecbotamab vedotin, an antibody-drug conjugate designed to target AXL, and ozuriftamab vedotin, an investigational therapy directed at ROR2.
Featured Articles
- Five stocks we like better than BioAtla
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.
